Literature DB >> 25005244

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.

H A F Stessman1, A Lulla2, T Xia3, A Mitra1, T Harding1, A Mansoor1, C L Myers4, B G Van Ness1, N G Dolloff2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25005244     DOI： 10.1038/leu.2014.214

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.

Authors:  Linhua Jin; Yoko Tabe; Kensuke Kojima; Yixin Zhou; Stefania Pittaluga; Marina Konopleva; Takashi Miida; Mark Raffeld
Journal:  Cancer Lett       Date:  2010-09-17       Impact factor: 8.679

2.  Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.

Authors:  N E Franke; D Niewerth; Y G Assaraf; J van Meerloo; K Vojtekova; C H van Zantwijk; S Zweegman; E T Chan; C J Kirk; D P Geerke; A D Schimmer; G J L Kaspers; G Jansen; J Cloos
Journal:  Leukemia       Date:  2011-09-23       Impact factor: 11.528

3.  MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.

Authors:  Manujendra N Saha; Hua Jiang; Jennifer Jayakar; Donna Reece; Donald R Branch; Hong Chang
Journal:  Cancer Biol Ther       Date:  2010-06-27       Impact factor: 4.742

4.  Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.

Authors:  Holly A F Stessman; Linda B Baughn; Aaron Sarver; Tian Xia; Raamesh Deshpande; Aatif Mansoor; Susan A Walsh; John J Sunderland; Nathan G Dolloff; Michael A Linden; Fenghuang Zhan; Siegfried Janz; Chad L Myers; Brian G Van Ness
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

5.  Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.

Authors:  Melissa G Ooi; Patrick J Hayden; Vassiliki Kotoula; Douglas W McMillin; Elpida Charalambous; Emily Daskalaki; Noopur S Raje; Nikhil C Munshi; Dharminder Chauhan; Teru Hideshima; Leutz Buon; Martin Clynes; Peter O'Gorman; Paul G Richardson; Constantine S Mitsiades; Kenneth C Anderson; Nicholas Mitsiades
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

6.  Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells.

Authors:  T Rückrich; M Kraus; J Gogel; A Beck; H Ovaa; M Verdoes; H S Overkleeft; H Kalbacher; C Driessen
Journal:  Leukemia       Date:  2009-02-19       Impact factor: 11.528

7.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

8.  Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.

Authors:  H A F Stessman; A Mansoor; F Zhan; S Janz; M A Linden; L B Baughn; B Van Ness
Journal:  Leukemia       Date:  2013-05-14       Impact factor: 11.528

Review 9.  Proteasome inhibitors in the treatment of multiple myeloma.

Authors:  J J Shah; R Z Orlowski
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

10.  Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.

Authors:  D Gutman; A A Morales; L H Boise
Journal:  Leukemia       Date:  2009-06-11       Impact factor: 11.528
View more
  7 in total

Review 1.  Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.

Authors:  Matthew Ho Zhi Guang; Amanda McCann; Giada Bianchi; Li Zhang; Paul Dowling; Despina Bazou; Peter O'Gorman; Kenneth C Anderson
Journal:  Leuk Lymphoma       Date:  2017-06-13

2.  ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors.

Authors:  Ravyn M Duncan; Leticia Reyes; Katelyn Moats; Reeder M Robinson; Sara A Murphy; Balveen Kaur; Holly A F Stessman; Nathan G Dolloff
Journal:  Cancer Res       Date:  2020-06-19       Impact factor: 12.701

3.  Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors.

Authors:  A K Mitra; U K Mukherjee; T Harding; J S Jang; H Stessman; Y Li; A Abyzov; J Jen; S Kumar; V Rajkumar; B Van Ness
Journal:  Leukemia       Date:  2015-12-29       Impact factor: 11.528

4.  Discovery platform for inhibitors of IgH gene enhancer activity.

Authors:  Nathan G Dolloff
Journal:  Cancer Biol Ther       Date:  2018-11-27       Impact factor: 4.742

5.  Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor.

Authors:  Reeder M Robinson; Leticia Reyes; Ravyn M Duncan; Haiyan Bian; Eric D Strobel; Sarah L Hyman; Allen B Reitz; Nathan G Dolloff
Journal:  Eur J Med Chem       Date:  2019-11-21       Impact factor: 6.514

6.  A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.

Authors:  A K Mitra; T Harding; U K Mukherjee; J S Jang; Y Li; R HongZheng; J Jen; P Sonneveld; S Kumar; W M Kuehl; V Rajkumar; B Van Ness
Journal:  Blood Cancer J       Date:  2017-06-30       Impact factor: 11.037

7.  Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.

Authors:  Ravyn M Thompson; Dominik Dytfeld; Leticia Reyes; Reeder M Robinson; Brittany Smith; Yefim Manevich; Andrzej Jakubowiak; Mieczyslaw Komarnicki; Anna Przybylowicz-Chalecka; Tomasz Szczepaniak; Amit K Mitra; Brian G Van Ness; Magdalena Luczak; Nathan G Dolloff
Journal:  Oncotarget       Date:  2017-05-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.